Ovarian cancer stem cells: A target for oncological therapy

Adv Clin Exp Med. 2018 Jul;27(7):1017-1020. doi: 10.17219/acem/73999.

Abstract

According to numerous studies, failures in treatment of ovarian cancer, i.e., a relapse and metastases, result from a small population of cancer stem cells (CSCs). They may also be responsible for tumor initiation. Cancer stem cells are resistant to chemoand radiotherapy. Eradication of CSCs may involve the application of salinomycin, metformin and Clostridium perfringens; the effect of anti-angiogenic factors remains controversial. Salinomycin is an antibiotic isolated from Streptomyces albus bacteria. Its CSC-eradicating effect has been demonstrated both in ovarian cancer cell lines and in women with breast cancer. Clostridium perfringens enterotoxin (CPE) has been demonstrated to destroy CSCs in ovarian cancer both in vivo and in vitro. Metformin, apart from its hypoglycemic effect, reduces the CSC population and inhibits the proliferation of neoplastic cells and angiogenesis. Cancer stem cells with expression of VEGFR1+ have been described as affecting circulating cancer cells and influencing the formation of metastases. Both positive and negative effects of anti-angiogenic therapy on the CSC population have been documented.

Keywords: Clostridium perfringens enterotoxin; angiogenesis; metformin; ovarian cancer stem cells; salinomycin.

Publication types

  • Review

MeSH terms

  • Animals
  • Cell Proliferation / drug effects
  • Enterotoxins / pharmacology
  • Female
  • Humans
  • Metformin / pharmacology
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / pathology*
  • Ovarian Neoplasms / pathology*
  • Pyrans / pharmacology

Substances

  • Enterotoxins
  • Pyrans
  • enterotoxin, Clostridium
  • salinomycin
  • Metformin